In this issue:
Autologous HSCT in elderly MM
Outcomes in high- vs. standard-risk MM after high-dose chemotherapy and autologous HSCT
CMV reactivation in MM
PIs and immunomodulators don’t overcome gain 1q21 in MM
Understanding hyperdiploidy in MM prognosis
CPD for relapsed/refractory MM
Elotuzumab + lenalidomide/ dexamethasone in relapsed MM
Consolidation melphalan and autologous SCT preferred over lenalidomide regimen
Carfilzomib or bortezomib with dexamethasone in relapsed/ refractory MM
Please login below to download this issue (PDF)